RANI — Rani Therapeutics Holdings, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1856725 ·
Last close
$0.56
Market Cap
$64.61M
52W High
$1.98
52W Low
$0.50
ADV30
522,863
Next earnings
2026-11-10
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,707,000 — -9,223,000 -7,729,000 52,529,000 3,620,000 11,175,000
Jun 2026 1,708,000 — -8,828,000 -7,391,000 60,843,000 4,868,000 12,858,000
Mar 2026 1,708,000 — -8,339,000 -7,033,000 51,879,000 9,644,000 16,336,000
Dec 2025 1,461,000 — -8,535,000 -10,305,000 58,621,000 18,618,000 17,109,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-22,990,000
Investing CF
$-41,118,000
Financing CF
$63,284,000
CapEx
$-267,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.19
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-154,733,000
Inventory
—
Receivables
$1,960,000
ST Investments
$41,668,000
EBIT TTM
$-33,830,000
Pretax Income TTM
$-34,316,000
Interest Exp TTM
$486,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,877,000
EBITDA
$-32,237,000
Free Cash Flow
$-8,874,375
Enterprise Value
$25,197,554
Total Cash
$53,391,000
Total Debt
$3,549,000
Shares Out
115,490,562
Trailing EPS
$-0.07
Book Value
$0.34
ROE
-172.1%
ROA
-53.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,633,000 -38,310,000 -29,673,000 58,621,000 17,109,000 33,010,000 -18,714,000
Dec 2024 1,028,000 -49,600,000 -30,018,000 36,634,000 33,141,000 1,992,000 -35,496,000
Dec 2023 0 -66,099,000 -33,970,000 57,916,000 32,473,000 12,866,000 -51,236,000
Dec 2022 0 -63,451,000 -30,588,000 108,027,000 34,023,000 36,855,000 -46,515,000

TTM Snapshot

Revenues TTM
$4,877,000
NetIncome TTM
$-30,141,000
OpCashFlow TTM
—
Assets (Latest)
$60,843,000
Forward EPS
$-0.19

Max Pain — expiry 2027-01-15

max pain strike: $1.00 · spot: $0.65 · call oi: 1,652 · put oi: 319
Expected Move to 2027-01-15: ±$0.20 (30.86%) — implied range $0.45 – $0.85 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TENX TENAX THERAPEUTICS, INC. $64.66M $1.42 —
KALA KALA BIO, Inc. $66.34M $3.43 —
CRBP Corbus Pharmaceuticals Holdings, Inc. $62.03M $3.01 —
GOSS Gossamer Bio, Inc. $67.52M $11.04 —
ACRV Acrivon Therapeutics, Inc. $61.28M $1.43 —

News headlines (Yahoo Finance, 1h cache)

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
2026-10-22 02:02 · Yahoo
Rani Therapeutics to Participate in the Chardan Healthcare Conference
2026-10-13 20:05 · Yahoo
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
2026-10-05 12:00 · Yahoo
Rani Therapeutics to Participate in Upcoming September Conferences
2026-09-08 12:00 · Yahoo
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
2026-08-13 20:05 · Yahoo
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
2026-08-04 12:00 · Yahoo
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
2026-05-26 12:00 · Yahoo
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
2026-08-16 20:01 · Yahoo
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-20 20:05 · Yahoo
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
2026-06-29 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.